000143209 001__ 143209
000143209 005__ 20240229112544.0
000143209 0247_ $$2doi$$a10.1016/j.jaad.2018.09.018
000143209 0247_ $$2pmid$$apmid:30244061
000143209 0247_ $$2ISSN$$a0190-9622
000143209 0247_ $$2ISSN$$a1097-6787
000143209 0247_ $$2altmetric$$aaltmetric:48829801
000143209 037__ $$aDKFZ-2019-00808
000143209 041__ $$aeng
000143209 082__ $$a610
000143209 1001_ $$aBrunssen, Alicia$$b0
000143209 245__ $$aA population-based registry study on relative survival from melanoma in Germany stratified by tumor thickness for each histologic subtype.
000143209 260__ $$aAmsterdam [u.a.]$$bElsevier$$c2019
000143209 3367_ $$2DRIVER$$aarticle
000143209 3367_ $$2DataCite$$aOutput Types/Journal article
000143209 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1555072653_31258
000143209 3367_ $$2BibTeX$$aARTICLE
000143209 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000143209 3367_ $$00$$2EndNote$$aJournal Article
000143209 520__ $$aDifferences in relative survival (RS) of melanoma between histologic subtypes were discussed to be mainly caused by tumor thickness.To investigate RS of melanoma, stratified by tumor thickness for each histologic subtype, and identify survival trends.With use of cancer registry data on melanoma cases (International Classification of Diseases, 10th Revision, codes C43.0-C43.9) diagnosed in Germany in 1997-2013, 5- and 10-year age-standardized RS stratified by histologic subtype and stratified or standardized by T stage was estimated by standard and modeled period analyses. We restricted 10-year RS analyses to patients younger than 75 years.We analyzed 82,901 cases. Overall, the 5- and 10-year RS rates were 91.7% and 90.8%, respectively. Prognosis worsened with increasing T stage for all histologic subtypes, but T-stage distribution varied substantially. Survival differences by histologic subtype were strongly alleviated after adjustment for T stage but remained significant. Overall, 5-year RS increased significantly (by 3.8 percentage points) between the periods 2002-2005 and 2010-2013. This increase was no longer seen after adjustment for T stage.Exclusion of cases on account of missing information on T stages, changes in the definition of T stages, and lack of information on screening and treatment limit our analyses.Differences in RS between histologic subtypes were strongly mediated by tumor thickness. Over time, RS of melanoma increased as a result of changes in T-stage distribution.
000143209 536__ $$0G:(DE-HGF)POF3-313$$a313 - Cancer risk factors and prevention (POF3-313)$$cPOF3-313$$fPOF III$$x0
000143209 588__ $$aDataset connected to CrossRef, PubMed,
000143209 7001_ $$0P:(DE-He78)bbfe0ebad1e3b608bca2b49d4f86bd09$$aJansen, Lina$$b1$$udkfz
000143209 7001_ $$aEisemann, Nora$$b2
000143209 7001_ $$aWaldmann, Annika$$b3
000143209 7001_ $$0P:(DE-He78)bf5409aed74a0923d9402c2c7ad620aa$$aWeberpals, Janick$$b4$$udkfz
000143209 7001_ $$aKraywinkel, Klaus$$b5
000143209 7001_ $$aEberle, Andrea$$b6
000143209 7001_ $$aHolleczek, Bernd$$b7
000143209 7001_ $$aZeissig, Sylke Ruth$$b8
000143209 7001_ $$0P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aBrenner, Hermann$$b9$$udkfz
000143209 7001_ $$aKatalinic, Alexander$$b10
000143209 7001_ $$aGroup, GEKID Cancer Survival Working$$b11$$eCollaboration Author
000143209 7001_ $$aGeiss, Karla$$b12
000143209 7001_ $$aMeyer, Martin$$b13
000143209 7001_ $$aLuttmann, Sabine$$b14
000143209 7001_ $$aStabenow, Roland$$b15
000143209 7001_ $$aHentschel, Stefan$$b16
000143209 7001_ $$aNennecke, Alice$$b17
000143209 7001_ $$aKieschke, Joachim$$b18
000143209 7001_ $$aSirri, Eunice$$b19
000143209 7001_ $$aEmrich, Katharina$$b20
000143209 7001_ $$aKajüter, Hiltraud$$b21
000143209 7001_ $$aMattauch, Volkmar$$b22
000143209 773__ $$0PERI:(DE-600)2001404-1$$a10.1016/j.jaad.2018.09.018$$gVol. 80, no. 4, p. 938 - 946$$n4$$p938 - 946$$tJournal of the American Academy of Dermatology$$v80$$x0190-9622$$y2019
000143209 909CO $$ooai:inrepo02.dkfz.de:143209$$pVDB
000143209 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)bbfe0ebad1e3b608bca2b49d4f86bd09$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000143209 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)bf5409aed74a0923d9402c2c7ad620aa$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000143209 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aDeutsches Krebsforschungszentrum$$b9$$kDKFZ
000143209 9131_ $$0G:(DE-HGF)POF3-313$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vCancer risk factors and prevention$$x0
000143209 9141_ $$y2019
000143209 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz
000143209 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bJ AM ACAD DERMATOL : 2017
000143209 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000143209 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000143209 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000143209 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List
000143209 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000143209 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000143209 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000143209 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000143209 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000143209 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bJ AM ACAD DERMATOL : 2017
000143209 9201_ $$0I:(DE-He78)C070-20160331$$kC070$$lKlinische Epidemiologie und Alternsforschung$$x0
000143209 9201_ $$0I:(DE-He78)L101-20160331$$kL101$$lDKTK Heidelberg$$x1
000143209 980__ $$ajournal
000143209 980__ $$aVDB
000143209 980__ $$aI:(DE-He78)C070-20160331
000143209 980__ $$aI:(DE-He78)L101-20160331
000143209 980__ $$aUNRESTRICTED